CROSSJECT |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.95 EUR | -1.02% |
|
-8.02% | -60.76% |
| May. 03 | Crossject: praised for extended agreement on Zepizure | CF |
| May. 02 | Crossject Signs A Geographic Extension of ZEPIZURE Commercialization Agreement in Europe | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2023 | 12.83M 13.94M | Sales 2024 * | 3.7M 4.02M | Capitalization | 74.63M 81.1M |
|---|---|---|---|---|---|
| Net income 2023 | -8M -8.69M | Net income 2024 * | -15M -16.3M | EV / Sales 2023 | 14.7 x |
| Net Debt 2023 * | 25.8M 28.04M | Net Debt 2024 * | 27.8M 30.21M | EV / Sales 2024 * | 27.7 x |
| P/E ratio 2023 * |
-3.42
x | P/E ratio 2024 * |
-4.88
x | Employees | 110 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 61.31% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | -1.02% | ||
| 1 week | -8.02% | ||
| Current month | -4.88% | ||
| 1 month | -4.41% | ||
| 3 months | -51.61% | ||
| 6 months | -55.38% | ||
| Current year | -60.76% |
1 week
1.92
2.13
1 month
1.902.29
Current year
1.835.96
1 year
1.835.96
3 years
1.415.96
5 years
1.045.96
10 years
1.0211.25
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 61 | 01-08-07 | |
Olivier Giré
PRN | Corporate Officer/Principal | - | 15-12-31 |
| Corporate Officer/Principal | - | 12-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Daniel Teper
BRD | Director/Board Member | 64 | 23-06-06 |
Eric Nemeth
BRD | Director/Board Member | 65 | - |
Philippe Monnot
CHM | Chairman | 65 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-17 | 1.95 | -1.02% | 48,627 |
| 24-05-16 | 1.97 | -2.48% | 63,580 |
| 24-05-15 | 2.02 | +0.50% | 27,485 |
| 24-05-14 | 2.01 | -0.25% | 55,139 |
| 24-05-13 | 2.015 | -4.95% | 48,197 |
Real-time Euronext Paris, May 17, 2024 at 11:35 am EDT
More quotes
Crossject specializes in manufacturing and marketing needleless drug self-injection. The group provides Zeneo, a prefilled and single-use device that can be used for intradermal, subcutaneous and intramuscular injections.
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.95
EUR
Average target price
5
EUR
Spread / Average Target
+156.41%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -60.76% | 80.62M | |
| +3.20% | 222M |
- Stock Market
- Equities
- ALCJ Stock